KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Debt to Equity (2016 - 2017)

Arbutus Biopharma (ABUS) has disclosed Debt to Equity for 2 consecutive years, with $0.07 as the latest value for Q4 2017.

  • Quarterly Debt to Equity rose 11.25% to $0.07 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $0.07 through Dec 2017, up 11.25% year-over-year, with the annual reading at $0.07 for FY2017, 11.25% up from the prior year.
  • Debt to Equity hit $0.07 in Q4 2017 for Arbutus Biopharma, down from $0.07 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.07 in Q3 2017 to a low of $0.06 in Q4 2016.